Interview with Wolf Kupatt, Managing Director, Baxter Germany
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
Address: Am Klopferspitz 19
82152 Planegg-Martinsried
Tel: +49. 89. 78 79 73 10
Web: http://www.chromotek.com/home/
Chromotek GmbH, a biotech spin-off from the LMu Munich founded in 2008, aims to establish Chromobodies®, (which are highly efficient functional binding reagents for a multitude of immuno-logical and biochemical applications), as superior substitutes for conventional antibodies in areas like proteome analysis, target screening/validation, cell sorting and live cell HCA. on the basis of its technology (patent pending). The team of 5 biologists around CEO Ulrich Rothbauer develops novel analytical and preparative solutions for the biomolecular research market. It has successfully launched the GFP-trap®, the best commercially available pull-down reagent for GFP and/or GFP fusion proteins.
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
See our Cookie Privacy Policy Here
